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Genetic loss-of-function studies in murine
tumor models have been essential in the
analysis of downstream mediators of onco-
genic transformation. Unfortunately, these
studies are frequently limited by the
availability of genetically modified mouse
strains. Here we describe a versatile method
allowing the efficient expression of an
oncogene and simultaneous knockdown
of targets of interest (TOI) from a single
retroviral vector. Both oncogene and TOI-
specific miR30-based shRNA are under the
control of the strong viral long terminal
repeat promoter, resulting in a single shared
RNA transcript. Using this vector in a mu-
rine syngeneic BM transplantation model
for BCR-ABL–induced chronic myeloid leu-
kemia, we find that oncogene expression
andtargetknockdowninprimaryhematopoi-
etic cells with this vector is efficient both in
vitro and in vivo, and demonstrate that Raf1,
but not BRAF, modulates BCR-ABL–depen-
dent ERK activation and transformation of
hematopoietic cells. This expression sys-
tem could facilitate genetic loss-of-function
studies and allow the rapid validation of
potential drug targets in a broad range of
oncogene-driven murine tumor models.
(Blood. 2011;118(8):2200-2210)
Introduction
Malignant cells frequently have rewired signaling networks
required for growth and survival. Identification of essential
nodes within these oncogene-mediated signaling networks
will be crucial for the development of novel anticancer therapies.
In vivo tumor models1-3 have been vital for the identification
of signaling pathways underlying malignant transformation,
an important aspect in the validation of potential thera-
peutic targets. A powerful approach to pin down essential
components of oncogenic signaling cascades in vivo has been
the use of murine BM transplantation (BMT) models in
combination with knockout BM cells.4-10 However, using
knockout mice to define critical signaling cascades or potential
drug targets can be time-consuming and may in some cases
be impossible. Some knockout mice have severe defects lead-
ing to embryonic lethality, others may not yet be available or
have to be crossed back to a syngeneic background to prevent
graft rejection, limiting efficiency and utility of this approach.
The discovery of RNA interference (RNAi) introduced a
new approach to inactivating genes in live cells. Subsequently,
the development of vector-expressed hairpin siRNAs (shRNA)
paved the way for prolonged, stable knockdown of genes.11
For in vivo application of siRNA-mediated gene suppression,
shRNAs have been accommodated for the expression from
retroviral and lentiviral vectors.12 The improvements in shRNA
delivery systems have made gene inactivation by RNAi a
rapid, versatile, and efficient approach to study gene func-
tion.13,14 The combination of retroviral hairpin siRNA de-
livery and retroviral infection/transplantation models in mice
should alleviate the inherent problems of transgenic/knockout
mice such as lack of suitable genetically modified mice be-
cause of embryonic lethality, time-consuming breeding or back-
crossing and limited availability. Furthermore, a functional
incomplete siRNA-mediated knockdown may mimic target
inhibition by a potential drug more closely than a knockout,
where gene function is completely abolished. However, expres-
sion of the oncogene and the target-of-interest (TOI)–specific
shRNA from 2 different vectors may lead to uncoupling of
expression and escape of oncogene transformed cells for
example, by silencing of the shRNA or by outgrowth of
single-infected cells.
Here we describe a reliable, highly versatile retroviral single
vector system in which a potent and durable knockdown of
variable TOIs by miR30-based shRNAs can be combined with
efficient expression of a desired oncogene or other transgene.
Directly coupling oncogene expression with TOI knockdown
was achieved by cloning an oncogene directly downstream of
a miR30-based shRNA (miRTOI) under control of the MSCV
retroviral long-terminal repeat (LTR) polymerase (Pol) II pro-
moter, resulting in one shared RNA transcript. By coupling
expression of the shRNA to the driving oncogene, we minimize
the chances for escape and ensure stable and durable TOI
knockdown in every transformed cell.
To validate our vector system, we turned to a well-
established murine retroviral syngeneic BMT model of BCR-
ABL induced myeloproliferative neoplasm2,15 to investigate the
role of Raf1 and BRAF in BCR-ABL–mediated leukemogen-
esis. Raf kinases are key enzymes to activate the MAPK/ERK
cascade,16 one of the central pathways activated by BCR-ABL.17
Using our coupled expression system, we here show that Raf1
but not BRAF modulates the BCR-ABL–mediated induction of
a chronic myeloid leukemia (CML)–like disease in mice.
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Methods
Growth factors and Abs
Recombinant murine IL-3 (mIL-3), IL-6 (mIL-6), and SCF (mSCF) were
purchased from R&D Systems. BCR-ABL and Abl was detected by
immunoblotting using an Abl-specific Ab 8E9 (BD Biosciences), -actin
Ab was from Sigma-Aldrich (AC-15). Tyrosine phosphorylation was
detected using a mixture of monoclonal anti-phosphotyrosine Ab 4G10
(Millipore) and PY20 (BD Biosciences). Raf1 (C-12), BRAF (H-145), and
STAT5 A/B (C-17) Abs came from Santa Cruz Biotechnology, p53 Ab came
from NovoCastra (CM5). Abs detecting phosphorylated AKT (Ser-473),
phosphorylated ERK1/ERK2, pan-AKT, and pan-ERK1/ERK2 were pur-
chased at Cell Signaling Technology. Monoclonal phospho-specific STAT5
A/B Ab was a generous gift from Tom Wheeler (Hamilton, New Zealand).
Plasmids
PLMPmiRCtrl was generated by subcloning the target-specific hairpin
sequence from pSM2c (nonsilencing shRNA vector for Ctrl miR; Open
Biosystems on BioCat) to pLMP (Open Biosystems) according to the
manufacturer’s instructions. Twenty-one–mer sequences for miRRaf1(1-3)
were calculated using the RNAi Central algorithm, miRRaf1(4-6), and
miRBRAF were calculated using the siRNA prediction software biopredsi
(www.biopredsi.org, developed by Novartis Institutes for BioMedical
Research, provided by Friedrich Miescher Institute for Biomedical Re-
search) and were adapted to miR30-based shRNA according to pLMP
manufacturer’s instructions. Oligonucleotide sequences serving as PCR
templates are: miRCtrl: TGCTGTTGACAGTGAGCGATCTCGCTT-
GGGCGAGAGTAAGTAGTGAAGCCACAGATGTACTTACTCTCGC-
CCAAGCGAGAGTGCCTACTGCCTCGGA; miRRaf1(1): 5-TGCTG-
TTGACAGTGAGCGCTGGTGGCTGACTGTGTGAAGATAGTGAA-
GCCACAGATGTATCTTCACACAGTCAGCCACCAATGCCTACTGC-
CTCGGA-3; miRRaf1(2): 5-TGCTGTTGACAGTGAGGGCTGCC-
GCCTCTCTGATTGGAGATAGTGAAGCCACAGATGTATCTCCA-
ATCAGAGAGGCGGCATTGCCTACTGCCTCGGA-3; miRRaf1(3):
5-TGCTGTTGACAGTGAGCGCAAGAAAGCCAGGAATACAGGTT-
AGTGAAGCCACAGATGTAACCTGTATTCCTGGCTTTCTTATGCCT-
ACTGCCTCGGA-3; miRRaf1(4): 5-TGCTGTTGACAGTGAGCGA-
CAGGAACACAAAGGTAAGAAATAGTGAAGCCACAGATGTATT-
TCTTACCTTTGTGTTCCTGGTGCCTACTGCCTCGGA-3; miRRaf1(5):
5-TGCTGTTGACAGTGAGCGATCAGGTATAAGTATTGTTTAATAGT-
GAAGCCACAGATGTATTAAACAATACTTATACCTGAGTGCCTACT-
GCCTCGGA-3; miRRaf1(6): 5-TGCTGTTGACAGTGAGCGCGA-
CATGAAATCCAACAATATATAGTGAAGCCACAGATGTATATATT-
GTTGGATTTCATGTCTTGCCTACTGCCTCGGA-3; miRBRAF(1):
5-TGCTGTTGACAGTGAGCGCAAGGGTGGAGATGAACTATAATAG-
TGAAGCCACAGATGTATTATAGTTCATCTCCACCCTTATGCCTACT-
GCCTCGGA-3; pLMPmiRp53 vector was kindly provided by S. Lowe
(Cold Spring Harbor Laboratory, New York, NY). pMmiRTOI-BCR-ABL
was cloned in 3 steps. First, the multiple cloning site (MCS) of the MIG-R1
vector was modified. To this purpose pcDNA3.1/Zeo() (Invitrogen) was
PmeI digested and the small fragment spanning the MCS of pcDNA3.1/
Zeo() between the 2 PmeI sites was ligated into HpaI-digested MIG-R1
vector resulting in MIG-Z. Then pBluescript BCR-ABL p185 was digested
with EcoRI and the BCR-ABL–encoding fragment was placed into the
EcoRI site of MIG-Z. Finally, pMmiRTOI–BCR-ABL was generated by
introducing a PCR product from pLMPmiRTOI (miRRaf1(1), miRBRAF(1),
miRp53, and miRCtrl), digested with BamHI and BglII into BamHI-digested
MIG-Z BCR-ABL construct (primer BamHI miR forward, 5-TGAGGATC-
CTAGGGATAACAGGGTAATTG-3 and BglII miR reverse, 5-TGA-
CAATTGAGATCTAAAAAAGTGATTTAATTTATACC-3). Supplemen-
tal constructs: pSuper.retro.puro shRNARaf1(1-4) plasmids were cloned
according to the manufacturer’s instructions (Oligoengine). pMBCR-ABL–
shRaf1 was cloned in 2 steps. First, a PCR product spanning H1 promoter and
shRNARaf1 was digested with XhoI and inserted into SalI linearized
MIG-R1 vector resulting in MIG H1 shRNARaf1. Second, pBluescript
BCR-ABL p185 was digested using EcoRI and introduced into EcoRI site
of MIG H1 shRNARaf1. Cloning details for generation of pMmiRTOI–BCR-
ABLp210 are available on request.
Cell culture
The IL-3–dependent murine myeloid cell line 32D and the IL-3–dependent
mouse pro-B-cell line Ba/F3 (both DSMZ) were cultured in RPMI 1640
(PAA Laboratories) supplemented with 10% FCS (PAA Laboratories),
2 ng/mL IL-3, penicillin/streptomycin, and l-glutamine. Phoenix E helper
virus-free ecotropic packaging cells (G. Nolan, Stanford, CA) and NIH/3T3
cells (DSMZ) were maintained in DMEM (PAA Laboratories) supple-
mented with 10% FCS. Cells were cultured in a humidified incubator at
37°C with 5% CO2.
Retrovirus preparation and generation of cell lines
A total of 2  106 Phoenix E cells were plated on 60-mm dishes and
transiently transfected using Lipofectamine 2000 (Invitrogen) 18 hours
later according to the manufacturer’s instructions. Medium was replaced
after 12 hours and retroviral stocks were collected at 12-hour intervals
beginning 24 hours after transfection. Retroviral titer were determined by
transduction of 5  104 NIH/3T3 cells with serial dilutions of retrovirus
supplemented with 4 g/mL polybrene (Sigma-Aldrich). The 48-hour
posttransduction percentage of infected cells was determined by flow
cytometric analysis of EGFP expression. Titer was calculated by multiplica-
tion of the total number of EGFP-positive cells with dilution factor of the
respective retroviral supernatant. To generate stably retroviral infected cell
lines derived from 32D or Ba/F3 cell line origin, 5  104 cells were
transduced by 2 to 4 rounds of spin infection (1200g, 32°C, 90 minutes)
every 12 hours in retroviral supernatant supplemented with 2 ng/mL IL-3,
4 g/mL polybrene (Sigma-Aldrich), and 20% RPMI 1640.
In vivo leukemogenesis studies
A suspension of 1  106 Ba/F3 cells infected with pMmiRRaf1-BCR-ABL
or pMmiRCtrl-BCR-ABL, previously maintained with 2 ng/mL IL-3 sup-
plement was injected into 6- to 8-week-old female Balb/c mice through tail
vein injection. Ba/F3-derived leukemic cells were rescued after 2 weeks
from spleens of the mice immediately after killing and cultured in RPMI
1640 containing 10% FCS for 7 days.
Transduction of murine BM and syngeneic
transplantation model
Murine BM was collected and transduced as described previously.18 Briefly,
BM was harvested from female BALB/c donor mice 4 days after injection
of 150 mg/kg 5-fluorouracil (5-FU; Medac) and prestimulated overnight in
BBMM medium (IMDM, 30% FCS, 1% BSA) containing growth factors
(10 ng/mL mIL-3, 10 ng/mL mIL-6, 50 ng/mL mSCF). Cells were trans-
duced by 4 rounds of spin infection (1200g, 32°C, 90 minutes) every
12 hours in retroviral supernatant (viral titers of 3.2-4.2  104) supple-
mented with growth factors, 4 g/mL polybrene (Sigma-Aldrich), and 20%
BBMM. Infection efficiency was determined by FACS analysis 12 hours
after last spin infection round (infection efficiencies of 10%-12%) and
adjusted to 10% EGFP-positive cells. The median EGFP intensity was
comparable, indicating comparable oncogene expression levels. Subse-
quently, cells were resuspended in HBSS (Sigma-Aldrich) and were used
for methylcellulose assays or for transplantation. For transplantation, cells
were mixed with untransduced BM to adjust to 2.5% EGFP-positive cells
(5000 EGFP-positive cells with 195 000 EGFP-negative cells), and injected
into the tail veins of lethally irradiated female BALB/c recipient mice.
Animals that received a transplant were monitored for signs of disease
development by serial measurement of peripheral blood (PB) counts. Mice
were caged in special caging system with autoclaved food and acidified
water at the Technical University of Munich in accordance with national
and institutional guidelines for animal care.
Clonal growth in methylcellulose
To analyze clonal growth, retrovirally transduced BM cells were re-
suspended in HBSS in a concentration of 1-4  104 cells containing
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2  103 EGFP cells per 100 L and mixed with 1.8 mL of MethoCult
4230 (StemCell Technologies) and 100 L of imatinib solution (final
concentration from 100nM to 2M) or vehicle HBSS. One thousand
EGFP BM cells in 1 mL of methylcellulose medium were plated in
duplicates in 12-well plates and colonies were photographed and counted
on day 10.
Quantitative PCR
RNA from cell lines and tissues was isolated with the RNeasy Mini Kit
(QIAGEN). cDNA was generated using the Titan One Tube RT-PCR Kit
(Roche Applied Science). qRT-PCR was performed using Platinum SYBR
Green qPCR SuperMIX UDG (Invitrogen) using primers specific for
murine GAPDH (fw: GGTCATCCCAGAGCTGAACGG, rev: CCT-
GCTTCACCACCTTCTTG) and murine Raf1 (fw1: TCTGAAGGT-
GAGAGGCCT, rev1: GGCATCGGTGTTCCAATCT, fw2: GTGATGCT-
GTCTACTCGGA, rev2: GGTCAACCACCTTTAGGATC). SD was
calculated as described by Livak and Schmittgen.19
Results
An alternative strategy to achieve simultaneous
expression of cDNAs and shRNAs in individual cells
Although it is possible to simultaneously overexpress an oncogene
and down-regulate a TOI by double infection of cells with 2 retro-
or lentiviral constructs, one encoding the oncogene, the other
encoding for a TOI-specific shRNA (shRNATOI), and either FACS
sort or select the cells with antibiotics, this strategy suffers from
several drawbacks. It is cumbersome and requires extensive
ex vivo manipulation of cells, which may compromise for example
the quality of HSCs, which cannot easily be kept in culture for
extended periods of time. Furthermore, expression of both con-
structs is influenced by the number and genomic location of
proviral integrations, which can lead to variable results. Therefore,
we designed a vector, which encodes both transgene mRNA and
shRNATOI on a single construct, thereby directly linking oncogene
and shRNATOI expression.
Most retroviral vectors express the oncogene under control of
the LTR promoter, a very strong RNA Pol II promoter. In contrast,
“classic” shRNAs are usually expressed from RNA Pol III promot-
ers such as U6 or H1. Initially, we used a MSCV-based retroviral
vector, which can express an oncogene via an LTR promoter
followed by EGFP translated from an internal ribosomal entry site
(IRES). In the 3 region of the construct, individual shRNATOI
expressed from a H1 promoter were cloned adjacent to the EGFP
(pMBCR-ABL-shTOI, supplemental Figure 1A, available on the
Blood Web site; see the Supplemental Materials link at the top of
the online article). This vector design led to good oncogene
expression (in this case the p185 BCR-ABL cDNA) and reasonable
knockdown of the TOI (in this experiment Raf1) in NIH/3T3 cells
(supplemental Figure 2). To further improve knockdown efficiency,
we inserted a second tandem shRNATOI targeting Raf1 with its own
H1 promoter in same orientation (supplemental Figure 1B) or
opposite orientation (supplemental Figure 1C). However, these
modifications did not lead to further improved knockdown efficien-
cies (data not shown). Suboptimal knockdown with these con-
structs might be because of the relatively weak RNA Pol III
promoters, driving the conventional shRNAs. MiR30-based
shRNAs (miRTOI) can be expressed from the powerful LTR Pol II
promoter and are effective in gene knockdown even when present
as a single copy in the genome.20,21 Therefore we designed an
MSCV-based retrovirus encoding both the target-specific Pol II–
driven miR30-based shRNA and the oncogene on a single con-
struct, both under the control of the same LTR promoter (pMmiRTOI-
oncogene, Figure 1). Importantly, coupling target-specific miRTOI
and oncogene by simultaneous expression from a single common
transcript should hinder silencing of the miRTOI over time even in
the presence of a strong negative selection and should enable
expression of both constructs in every transduced cell without time
consuming selection or cell sorting of double-positive cells (Figure
Figure 1. A retroviral vector system encoding an
oncogene and an shRNA under the control of a
single promoter. Schematic representation of the single-
vector design of pMmiRTOI oncogene. Oncogene and a
miR30-based TOI-specific shRNA are expressed from
the same RNA Pol II promoter LTR. EGFP is expressed
via an IRES. The DNA is transcribed by RNA Pol II
resulting in one unique mRNA transcript encoding for
target-specific miR, oncogene and EGFP as fluorescent
marker. Dicer processes miR30 sequence of the tran-
script or ribosomes initiate translation of the oncogene
and EGFP.
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1). In addition, we established a sequence and ligation independent
cloning strategy22 for easy exchange of the miRTOI cassette
(supplemental Figure 3).
MiR30-based shRNAs targeting Raf1 show efficient
knockdown when coupled to BCR-ABL expression
Next we wished to confirm the functionality of this vector system
in a clinically relevant leukemia model. We decided to investigate
the role of Raf1 in the well-established BCR-ABL–driven murine
retroviral syngeneic CML transplantation model.2,9,15,23 Previous
studies demonstrated a role for Raf1 in activation of the MAPK/
ERK signaling cascade,16,24,25 one of the central signal transduction
cascades of BCR-ABL.17,26,27 In addition, Raf1 has been implicated
in BCR-ABL–mediated transformation in vitro.26 However, the
role of Raf1 has not been assessed in a CML transplantation mouse
model in vivo, possibly because Raf1 knockout BM is not available
because of embryonic lethality of Raf1/ mice.28 Because Raf1 is
a drugable kinase, it is of great interest as a potential molecular
target in CML.
Thus, we cloned 6 different miR30-based Raf1 shRNAs (miRRaf1)
into the retroviral pLMP vector (Figure 2A top panel).20 Three of 6
pLMPmiRRaf1 constructs were effective, resulting in nearly undetectable
Raf1 protein levels in NIH/3T3 cells (Figure 2B). We subcloned the
most efficient miRRaf1 cassette (indicated by a single asterisk) into the
BCR-ABL–encoding pMmiRTOI-oncogene vector, resulting in
pMmiRRaf1–BCR-ABL (Figure 2A bottom panel) and analyzed the
efficacy of parallel oncogene expression and target knockdown. Both
knockdown of the target and oncogene expression with this vector were
highly effective (Figure 2C).
In addition, we also cloned a p53-specific miR30-based
shRNA (miRp53) in the BCR-ABL–encoding pMmiRTOI-oncogene
vector and showed functionality of the miRp53 in both vectors
(Figure 2D-E). p53 knockdown previously has been shown to lead
to an acceleration of BCR-ABL–induced leukemogenesis in mice29
Figure 2. Effective target silencing and oncogene
expression can be obtained from one unique mRNA.
(A) Retroviral vectors used to deliver shRNAs to mam-
malian cells. PLMP vector encodes for a miR30-based
target-specific shRNA under LTR promoter control.
PMmiRTOI–BCR-ABL vector encodes for target-specific
miR and p185 BCR-ABL. Provirus layouts are shown
with open arrows indicating active promoters and 2 in-
verted block arrows representing shRNA stem se-
quence. (B) Western blot analysis of NIH/3T3 cells
transduced with different Raf1 miR in pLMP after puro-
mycin selection. (C) Ba/F3 cells retrovirally infected
with pMmiRRaf1–BCR-ABL or pMmiRCtrl–BCR-ABL
construct. (D) Western blot analysis of NIH/3T3 cells
transduced with p53 miR in pLMP after puromycin
selection. To induce p53, cells were UV irradiated
4 hours prior harvesting. (E) Western blot analysis of
Ba/F3 cells retrovirally infected with pMmiRp53–BCR-ABL or
pMmiRCtrl–BCR-ABL. (F-G) Raf1 knockdown disrupts
BCR-ABL–dependent MAPK signaling. 32D (F) or Ba/F3
cells (G) retrovirally infected with pMmiRCtrl–BCR-ABL
or pMmiRRaf1–BCR-ABL were maintained in IL-3–
containing medium, then starved for 4 hours and ana-
lyzed for MAPK signaling by Western blot as indicated.
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and thus could serve as a positive readout control in further
experiments. In summary, these data demonstrate that miRTOI
expressed together with the BCR-ABL oncogene on one single
mRNA transcript driven by the LTR Pol II promoter leads both to
effective TOI knockdown and expression of the oncogene.
Next we examined the effects of simultaneous Raf1 knock-
down and BCR-ABL expression on ERK activation in 2 hemato-
poietic cytokine-dependent cell lines. We infected 32D cells
(IL-3–dependent murine myeloid cell line, Figure 2F) and Ba/F3
(IL-3–dependent murine pro-B-cell line, Figure 2G) with
pMmiRRaf1–BCR-ABL or pMmiRCtrl–BCR-ABL retroviruses. On
BCR-ABL expression, these cell lines become growth factor
independent. Transduced cells were cultured with IL-3 or starved
for 4 hours in IL-3 and serum-free medium, subsequently har-
vested and subjected to Western blot analysis. Also in these cells,
the pMmiRRaf1–BCR-ABL vector led to both robust oncogene
expression and effective TOI knockdown. In the absence of
growth factors, Raf1 knockdown resulted in a significant re-
duction of ERK phosphorylation in BCR-ABL–positive 32D and
Ba/F3 cells (Figure 2F-G). However, this effect of the Raf1
knockdown was not observed in IL-3–stimulated cells. Thus,
Raf1 seems to be important for BCR-ABL–induced activation of
the MAPK/ERK cascade but dispensable for IL-3–mediated
ERK activation.
Next we analyzed whether our construct enabled sustained
knockdown over a longer period of time both in vitro and in vivo as
knockdown of Raf1 might confer negative selection pressure and,
for example, lead to silencing of the shRNA expression over time.
To this end, Ba/F3 cells were transduced with pMmiRRaf1–BCR-
ABL or pMmiRCtrl-BCR-ABL. Cells were sorted for EGFP,
deprived of IL-3, and then either kept in culture or injected into
syngeneic Balb/c mice. Four to 6 weeks later cultured cells or
spleen cells from diseased mice were analyzed for BCR-ABL
expression and knockdown efficiency (Figure 3A).
Western blot analysis showed sustained BCR-ABL expression
and strong Raf1 knockdown ( 90%) over a period of  4 weeks
both in vitro and in vivo (Figure 3A). Interestingly, miRRaf1-
encoding cells showed reactivation of p-ERK over time, indicating
that activation of the MAPK/ERK cascade is indispensable for the
survival of BCR-ABL–positive cells (Figure 3B). Because the
Raf1 knockdown remained complete over time, other mechanisms
may lead to ERK activation. One possible candidate might be BRAF,
another Raf family member and activator of MAPK/ERK cascade, but
neither BRAF protein expression (Figure 3B) nor its activation was
elevated (Figure 3C). Alternatively secreted or circulating cyto-
kines might reactivate ERK independent of BCR-ABL signaling.
IL-3, for example, is able to activate ERK in the absence of Raf1
(Figure 2F-G).
Figure 3. Target silencing and oncogene expres-
sion are both effective and persistent. (A) Scheme of
experimental setup: FACS-sorted Ba/F3 cells expressing
pMmiRCtrl–BCR-ABL or pMmiRRaf1–BCR-ABL as shown in
Figure 2G, were deprived of IL-3 and either kept in
culture or injected intravenously into BALB/c mice.
After 2 weeks, cells were reisolated from mouse spleens
and cultured for 1 more week. After 4-5 weeks cultured
cells or spleen cells from 2 individual mice per group
were analyzed for (B) BCR-ABL expression and Raf1
knockdown efficiency by Western blot analysis. (C) The
membrane was stripped and reprobed with anti–p-ERK,
anti–p-AKT, and anti–p-STAT5 Abs as indicated.
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Effects of Raf1 suppression on BCR-ABL–mediated
colony growth of primary HSCs in methylcellulose
We next tested the functionality of the pMmiRTOI–BCR-ABL
vector in primary murine BM (BM) cells. Primary murine BM
cells, harvested from 5-FU–pretreated donor mice, were transduced
with pMmiRRaf1–BCR-ABL or pMmiRCtrl-BCR-ABL retro-
virus, BCR-ABL expression and Raf1 knockdown was confirmed
(Figure 4A and B) and cells were starved for 6 hours in cytokine-
free, serum-reduced medium. Again, simultaneous BCR-ABL
expression and Raf1 knockdown led to a reduction in the phosphor-
ylation of ERK (Figure 4C).
To determine the role of Raf1 in BCR-ABL–mediated
transformation of primary BM cells, cells were plated into
methylcellulose in the absence of growth factors and colonies
were quantified 10 days later. We observed smaller colonies and
a significant reduction in colony numbers by Raf1 knockdown
compared with control cells, indicating that Raf1 mediates
BCR-ABL–induced ERK activation and plays an important role
in the transformation of primary hematopoietic cells by BCR-
ABL in vitro (Figure 4D).
To test whether a combination of Raf1 knockdown and BCR-
ABL kinase inhibition could further reduce colony formation, we
used the BCR-ABL inhibitor imatinib. Although imatinib alone is
able to suppress colony formation of BCR-ABL–positive BM cells,
additional Raf1 knockdown potentiates imatinib-induced growth
inhibitory effects in this assay (Figure 4D). Similar results were
obtained using a vector encoding for the BCR-ABLp210 instead of
the BCR-ABLp185 isoform (supplemental Figure 5A-B). In addi-
tion, we investigated the impact of Raf1 knockdown on leuke-
mogenesis mediated by imatinib-resistant BCR-ABL mutants
BCR-ABLT315I and BCR-ABLY253H. The transforming capacity of
both mutants was strongly reduced on Raf1 down-regulation
(supplemental Figure 5C-D). Thus, a combination of Raf1 and
Abl inhibition may be a promising approach in BCR-ABL–
positive disease.
Inactivation of Raf1 by RNAi delays onset of
leukemia in a murine model of CML
First, to exclude general toxicity of Raf1 knockdown in hematopoi-
etic cells, we tested the effect of Raf1 down-regulation alone on
normal hematopoiesis in vitro as well as in vivo. On Raf1 knock-
down, there was no difference observed regarding colony-forming
ability in semisolid medium in vitro (supplemental Figure 6).
Furthermore, mice transplanted with Raf1 knockdown BM recon-
stituted normally (supplemental Figure 7A-B) and Raf1 knock-
down had no effect on short- or long-term generation of myeloid,
B, or T cells (supplemental Figure 7C), indicating that Raf1 knock-
down does not interfere with normal hematopoiesis. This finding is
in agreement with a recent report demonstrating no obvious
phenotype of Raf1 knockout in adult mice.30
Then, to confirm the applicability of the vector system for
in vivo approaches, we generated mice developing BCR-ABL–
positive leukemia by the retroviral syngeneic transplantation
method. To this end BM derived from 5-FU–pretreated donor mice
was infected with pMmiRRaf1–BCR-ABL, pMmiRp53–BCR-ABL,
or pMmiRCtrl–BCR-ABL retroviruses and injected into the tail
veins of lethally irradiated recipient BALB/c mice (see “Methods,”
for summary of all transplantations see Table 1). All mice that
received pMmiRCtrl–BCR-ABL–infected cells developed a CML-
like disease with a very short latency and 100% penetrance
characterized by a high percentage of EGFP, Mac1/Gr-1 cells in
their peripheral blood within 18 days (Figure 5B). The mice
Figure 4. Raf1 depletion attenuates BCR-ABL–
induced transformation of murine BM cells in vitro.
5-FU–enriched mouse BM-derived progenitor cells
were infected either with pMmiRCtrl–BCR-ABL or
pMmiRRaf1–BCR-ABL retrovirus. (A) Expression levels of
Raf1 were analyzed by qRT PCR (TaqMan) in EGFP
cells 5 days after transduction. Results were normal-
ized to the housekeeping gene GAPDH. (B) Raf1 knock-
down efficacy was verified by Western blot. (C) Retro-
virally infected BM cells were starved for 6 hours in
RPMI medium containing 3% FCS and no cytokines
and p-ERK status was determined by Western blot.
(D) Results of methylcellulose colony formation assays.
PMmiRCtrl–BCR-ABL and pMmiRRaf1–BCR-ABL–
expressing murine BM cells were plated in methylcellu-
lose without growth factors in the absence or presence
of imatinib as indicated. Representative photographs of
methylcellulose colonies of pMmiRCtrl–BCR-ABL or
pMmiRRaf1–BCR-ABL–transduced BM cells are shown
and CFUs were quantified 10 days after plating. Results
shown are from 1 of 3 independent experiments per-
formed in duplicates. P values were determined by
Student t test.
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succumbed to leukemia within 5 weeks, demonstrating that the
pMmiRCtrl–BCR-ABL construct can efficiently induce a CML-like
disease in this model (Figure 5A). Recipients of pMmiRRaf1–BCR-
ABL–transduced BM cells showed a substantially prolonged
survival (Figure 5A). Onset and progression of the disease was
significantly delayed in Raf1 knockdown animals as depicted by
lower proportion of leukemic white blood cells (WBCs) in the
peripheral blood (Figure 5B) and lower peripheral leukocyte counts
(Figure 5C). These results were verified using a second indepen-
dent miRRaf1 (Figure 2B indicated by double asterisks, and
supplemental Figure 8).
As expected, p53 knockdown in this system slightly al-
though nonsignificantly accelerated the progression of leukemia in
this highly aggressive CML model (Figure 5D).29 Sustained and
efficient Raf1 and p53 knockdown could be demonstrated in
spleen cells of diseased mice, highlighting the efficient and durable
in vivo knockdown conferred by this vector design (Figure 5E-F).
Thus, development of leukemia was delayed but not completely
abolished in Raf1 knockdown mice. pMmiRRaf1–BCR-ABL–
expressing cells, as shown in Figure 3C, showed reactivation of
p-ERK over time. Therefore, compensatory mechanisms may
lead to ERK activation, because the Raf1 knockdown remained
complete over time. One possible candidate might be BRAF,
another Raf family member and activator of the MAPK/ERK
cascade.
BRAF is dispensable for BCR-ABL–dependent transformation
Two studies suggested an involvement of BRAF in BCR-ABL–
mediated transformation by overexpressing or deleting the BRAF
inhibitor SPA-1.31,32 As BRAF knockout mice are embryonic
lethal33 studies using BRAF knockout BM have not been per-
formed. Here we analyzed the function of BRAF in comparison to
Raf1 for BCR-ABL–mediated transformation using our vector
system. Interestingly, in contrast to Raf1, BRAF knockdown had
no impact on BCR-ABL–dependent activation of ERK in vitro
(Figure 6A). In addition, BRAF depletion in primary murine BM
cells did not alter colony-forming numbers and shape in a
methylcellulose assay, suggesting that BRAF is dispensable for
BCR-ABL–mediated transformation in this assay (Figure 6B).
We finally also investigated the role of BRAF for BCR-ABL–
mediated leukemogenesis in the previously described murine CML
model (for summary of all transplantations see Table 1). Neither
knockdown of Raf1 nor of BRAF had an influence on the
phenotype of the disease (supplemental Figure 4). However, in
contrast to Raf1, BRAF knockdown did not affect BCR-ABL–
dependent leukocytosis, leukemic burden in the peripheral blood
(Figure 6D-E) or overall survival despite very efficient BRAF
knockdown (Figure 6C,F).
Discussion
In a genetically complex disease like cancer, which is further
complicated by the diverse interactions between the tumor cell and
the host organism, in vivo genetic loss-of-function studies in the
mouse are an invaluable tool to determine functional dependencies
within the tumor network. Before the advent of RNAi technology,
knockout mice were central for the study of loss-of-function
effects. To generate suitable tumor models, usually a tumor-
initiating oncogenic line has to be crossed to the knockout mouse
line in time-consuming breedings. For hematopoietic malignan-
cies, introduction of an oncogene into HSCs derived from respec-
tive knockout mice by retroviral infection and subsequent transplan-
tation into irradiated host animals accelerates the analysis, and is
also restricted by the availability of the respective knockout strain
as well as the requirement for an immunologically compatible
donor mouse strain. These obstacles so far have strongly impacted
a more widespread use of genetic loss-of-function studies in the
analysis of hematopoietic malignancies. In 2002, Cullen and
colleagues discovered that hairpin sequences of the endogenous
microRNA (miR) miR30 can be replaced by a target-specific
sequence, generating a synthetic, target-specific miR30-based
shRNA.21 In contrast to conventional shRNAs, these miR30-based
shRNAs can be transcribed by RNA Pol II promoters.21,34-36 This
feature of miR30-based shRNAs seemed to increase the efficiency
of target knockdown in vivo compared with regular shRNAs
Table 1. Summary of transplantation experiments
Genotype
No. of
mice
Mean
fluorescence
EGFP cell
transplantations
Total cell
transplantations
Median
survival time,
d (range)
Median WBC day 18,
103/L (range)
pMmiRCtrl–BCR-ABL 5 63.7 5000 200 000 23.2 (19-30) 85 (42-135)
pMmiRRaf1–BCR-ABL 4 60.5 5000 200 000 31.3 (26-34) 52 (23-88)
pMmiRp53–BCR-ABL 5 59.6 5000 200 000 22.2 (19-27) 129 (46-242)
pMmiRCtrl–BCR-ABL 3 178.6 5000 200 000 25.0 (22-27) 188 (169-209)
pMmiRRaf1–BCR-ABL 3 160.8 5000 200 000 40.0 (34-50) 98 (20-150)
pMmiRp53–BCR-ABL 3 138.7 5000 200 000 21.3 (19-24) ND
pMmiRCtrl–BCR-ABL 5 31.0 5000 190 000 24.6 (22-28) 107 (78-140)
pMmiRRaf1–BCR-ABL 5 23.9 5000 190 000 33.4 (24-41) 69 (40-124)
pMmiRCtrl–BCR-ABL 5 31.1 5000 190 000 29.8 (18-37) 52 (31-86)
pMmiRRaf1–BCR-ABL 4 27.5 5000 190 000 41.0 (32-46) 26 (10-39)
pMmiRBRAF–BCR-ABL 5 32.5 5000 190 000 29.2 (25-32) 82 (31-168)
pMmiRCtrl–BCR-ABL 5 34.2 5000 200 000 25.0 (19-29) ND
pMmiRRaf1–BCR-ABL 5 28.0 5000 200 000 34.3 (31-38) ND
pMmiRBRAF–BCR-ABL 5 35.0 5000 200 000 24.4 (21-30) ND
pMmiRCtrl–BCR-ABL 10 65.6 5000 200 000 25.7 (21-29) 101 (33-228)
pMmiRRaf1(6)–BCR-ABL 10 50.9 5000 200 000 39.6 (25-70) 23 (5-70)
WBC indicates white blood cell.
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expressed from Pol III promoters, as shown in a series of elegant
studies.20,35,37 Furthermore, some endogenous microRNAs have
been found within introns or 3 UTRs of other genes,38 suggesting
that cotranscription of miRs together with other genes may be
feasible. Taking advantage of these characteristics of miR-based
shRNAs, we now have developed an RNAi-based system that
alleviates most of the problems entailed in the “classic” approach
using knockout mice. The system described in this study is
designed for simultaneous expression of a miR30-based shRNA
and an oncogene from a single transcript. This facilitates stable and
durable target knockdown in every oncogene-expressing cell and
distinguishes the present vector design from other polycistronic
single-vector designs for coexpression of shRNAs and trans-
genes.39 Because oncogene and miRTOI are derived from the same
transcript, transfected cells selecting for expression of the onco-
gene automatically coselect for the miRTOI. Thus, this vector is
suited for the investigation of oncogenic signaling networks, in
which down-regulation of crucial signaling targets may lead to a
strong negative selection against shRNA-expressing cells. In
addition, combined expression of oncogene, miRTOI and EGFP
eliminate the need for cell sorting or antibiotic selection. The
single-vector design will be particularly beneficial in target cells,
which can only be temporarily cultured ex vivo or are only
moderately permissive for transduction, such as embryonic or
HSCs and also other primary cells. Here the single-vector system
allows introduction of both miRTOI and transgene by a single-step
transduction. In principle, any target gene of interest for which
suitable shRNAs are available can be stably down-regulated in
combination with the expression of a positively selected oncogene.
In contrast to the approach where the shRNA is transduced into a
transgenic animal with an established disease in our model the
disease has to establish in the setting of knockdown of potential
mediators, which is one potential drawback of the system. Never-
theless, this system is highly flexible and not only limited to studies
on oncogenic signaling cascades. It can for example also be used to
express a mutant form of a given protein while knocking down the
endogenous wildtype protein, thus mimicking gene replacement.
We additionally established a cloning strategy to facilitate introduc-
tion of the miRTOI cassette into a transgene-encoding vector
harnessing sequence and ligation independent cloning22,40 (SLIC;
supplemental Figure 3), thereby enabling subcloning of whole
miR30-based shRNA libraries.34,41
We analyzed the functionality of this vector system in a BM
transduction transplantation model for CML. The gold standard
Figure 5. Raf1 depletion attenuates BCR-ABL–induced leukemogenesis in a murine transfection/transplantation model. Mice transplanted with pMmiRRaf1–
BCR-ABL show delayed onset and slower progression of disease. (A) Raf1 knockdown in BCR-ABL–positive cells prolongs overall survival of mice in a BM transplantation
model. Kaplan-Meier plot detailing survival times of mice transplanted with pMmiRCtrl–BCR-ABL (n  23) or pMmiRRaf1–BCR-ABL (n  21) in 5 independent experiments.
(B) Proportion of leukemic WBCs in the peripheral blood of mice that received transplants at indicated time points (day 15: pMmiRCtrl–BCR-ABL n  10; others n  9). P value
was determined by Student t test. (C) White blood cell counts from peripheral blood of mice that received transplants of one experiment at indicated time points (n  3 for each
group). (D) p53 knockdown in BCR-ABL–positive cells has no significant impact on overall survival in a BM transplantation model. Kaplan-Meier plot detailing survival times of
mice transplanted with pMmiRCtrl–BCR-ABL (n  8) or pMmiRp53–BCR-ABL (n  8) in 2 independent experiments. (E-F) Target knockdown is durable in a BM transplantation
model. qRT PCR (TaqMan) analysis of splenocytes isolated from moribund mice with 80% EGFP-positive splenocytes. (E) Raf1 and (F) p53 mRNA levels were normalized to
the housekeeping gene GAPDH. Values were determined from 2-3 mice per group measured in duplicates.
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for CML therapy is the BCR-ABL kinase inhibitor imatinib. The
majority of patients with BCR-ABL–positive CML show excellent
responses to tyrosine kinase inhibitor treatment.42,43 However, the
persistence of BCR-ABL–positive cells in imatinib-treated patients
indicates that inhibition of the Abl kinase activity alone might not
be sufficient to eradicate the leukemia. Combining a BCR-ABL
tyrosine inhibitor with inhibitors of its downstream signaling
targets may improve CML therapy. Inhibitors that target various
stages of the Ras signaling pathway, such as farnesyl transferase,
MEK1, PI3K, mTOR, and cyclin-dependent kinases (CDKs), have
been shown in vitro to have synergistic or additive effects in
preventing BCR-ABL–mediated transformation.44-47 Only a few of
the molecules involved in BCR-ABL signaling have so far been
directly examined for their role in mediating BCR-ABL–induced
transformation in vivo, an important aspect in the validation of
potential therapeutic targets.3,44,48,49 Here we show that Raf1 but
not BRAF is an important intermediate in the BCR-ABL signaling
cascade in vivo, required for the efficient activation of the
promitogenic MAPK/ERK pathway. Interestingly, a recent study
does also show a role of Raf1 but not BRAF in the pathogenesis of
lung cancer.30
Several Raf inhibitors have already entered clinical trials and
especially in melanoma with BRAF mutations the clinical
results are very encouraging50 However, a series of papers could
demonstrate that on BRAF inhibition the MAPK/ERK cascade
can get paradoxically activated by various mechanisms which
may lead to acceleration of the malignant growth on BRAF
inhibition. It is thus important to carefully study the effects of
the inhibition of Raf isoforms on malignant growth in every
tumor type. According to our results, BRAF inhibitors are
predicted to be of limited use in the treatment of CML, whereas
inhibition of Raf1 would seem to be more promising. However,
Raf1 knockdown alone was not sufficient to prevent leukemia
onset in mice. Thus, combinatorial studies of BCR-ABL inhibi-
tors and inhibitors targeting Raf1 may be warranted in Philadel-
phia chromosome–positive leukemia.
The outlined vector system pMmiRTOI-oncogene represents a
very efficient and versatile approach to perform loss-of-function
Figure 6. BRAF is dispensable for BCR-ABL–mediated
ERK activation and transformation in vitro and
in vivo. (A) Verification of the pMmiRBRAF–BCR-ABL
vector. Ba/F3 cells were retrovirally infected with indi-
cated vectors and BCR-ABL, BRAF, Raf1, p-ERK, ERK,
and actin levels were determined by Western blot
analysis. (B) Results of methylcellulose colony forma-
tion assays. Murine BM cells were retrovirally infected
with pMmiRCtrl–BCR-ABL, pMmiRRaf1–BCR-ABL, or
pMmiRBRAF–BCR-ABLandplated inmethylcellulosemedium
without growth factor supplement in the absence or pres-
ence of imatinib as indicated. Representative photographs
of methylcellulose colonies of pMmiRCtrl–BCR-ABL,
pMmiRRaf1–BCR-ABL, or pMmiRBRAF–BCR-ABL–trans-
duced BM cells are shown (top panel) and CFUs were
quantified 10 days after plating (bottom panel). Results
shown are from 1 of 3 independent experiments performed
in duplicates. P values were determined by Student t test.
(C) Functional analysis of pMmiRBRAF–BCR-ABL in murine
primary BM. BM of 5-FU–pretreated donor mice was
transduced with indicated vectors, sorted by FACS, and
analyzed by Western blot. (D) BRAF knockdown has
no effect on BCR-ABL–mediated leukocytosis in a BM
transplantation model for CML. Mice were transplanted
with pMmiRCtrl–BCR-ABL (n 5), pMmiRRaf1–BCR-ABL
(n 4), or pMmiRBRAF–BCR-ABL (n 5) transduced BM
and WBC counts and (E) proportion of leukemic cells in
peripheral blood were determined. (F) Kaplan-Meier plot
detailing survival times of mice transplanted with
pMmiRCtrl–BCR-ABL (n  10), pMmiRRaf1–BCR-ABL
(n  9) or pMmiRBRAF–BCR-ABL (n  10). Data from
1 of 3 independent experiments are shown.
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studies in hematologic malignancies. By strongly facilitating the
characterization of oncogenic signaling networks, this system
should help to establish a hierarchical map of functionally relevant
genes in a defined tumor context and supply new targets for drug
development.
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